Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs XTL Biopharmaceuticals Ltd. (XTLB)

Alzamend Neuro, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Alzamend Neuro, Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($7.5M and $7.3M). Across the 8 metrics below, XTL Biopharmaceuticals Ltd. leads on 5 and Alzamend Neuro, Inc. on 3.

Valuation

Metric ALZN XTLB Biotechnology median
P/E n/m n/m 10.26
P/S n/m 1.19 9.18
P/B 1.18 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.05 n/m 0.65
EV/Sales n/m 1.10 8.98
Earnings yield (150.33%) (28.44%) (34.89%)
Free cash flow yield (104.25%) (158.67%) (24.52%)

Profitability

Metric ALZN XTLB Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) 0.00% (50.12%)
Return on assets (122.36%) 0.00% (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN XTLB Biotechnology median
Revenue growth (TTM) — (12.71%) 6.26%
EPS growth (last fiscal year) 76.77% (409.84%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 3.01 0.70 4.89
Net debt to EBITDA 0.08 (0.11) 1.01

Dividend

Metric ALZN XTLB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALZN XTLB Biotechnology median
Market cap 7.48m 7.25m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack